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Modifier screens have been powerful genetic tools to define
signaling pathways in lower organisms. The identification of
modifier loci in mice has begun to allow a similar dissection of
mammalian signaling pathways. Transgenic mice (Btklo) expressing
25% of endogenous levels of Bruton’s tyrosine kinase (Btk) have B
cell functional responses between those of wild-type and Btk2/2
mice. We asked whether reduced dosage or complete deficiency of
genes previously implicated as Btk regulators would modify the
Btklo phenotype. We used two independent assays of Btk-depen-
dent B cell function. Proliferative response to B cell antigen recep-
tor cross-linking in vitro was chosen as an example of a relatively
simple, well-defined signaling system. In vivo response to type II
T-independent antigens (TI-II) measures complex interactions
among multiple cell types over time and may identify additional
Btk pathways. All modifiers identified differentially affected these
two assays, indicating that Btk mediates these processes via
distinct mechanisms. Loss of Lyn, PTEN (phosphatase and tensin
homolog), or SH2-containing inositol phosphatase suppressed the
Btklo phenotype in vitro but not in vivo, whereas CD19 and the
p85a form of phosphoinositide 3-kinase behaved as Btklo enhanc-
ers in vivo but not in vitro. Effects of Lyn, PTEN, or p85a haploin-
sufficiency were observed. Haploinsufficiency or complete defi-
ciency of protein kinase C b, Fyn, CD22, Gaq, or Ga11 had no
detectable effect on the function of Btklo B cells. A transgenic
system creating a reduction in dosage of Btk can therefore be used
to identify modifier loci that affect B cell responses and quantita-
tively rank their contribution to Btk-mediated processes.
In vivo genetic analysis is a powerful approach to define the
relative contribution of signaling interactions to physiological
processes. Small genomes, ease of mutagenesis, and rapid gen-
eration time have made Drosophila melanogaster, Caenorhabditis
elegans, and Saccharomyces cerevisiae the major models for
genetic dissection of eukaryotic signaling pathways. Although
there are some examples of large-scale genetic screens in mice
(1–3), time, space, and financial resources generally limit mam-
malian genetic studies to targeted mutations in known genes or
the characterization of naturally occurring mutations.
In a commonly used type of genetic screen, organisms carrying
a defined mutation affecting the process of interest are further
mutagenized and screened for second site mutations, or modi-
fiers, that enhance (increase) or suppress (reduce) the severity
of the parental phenotype (4, 5). The initial mutation often
renders the system responsive to subtle changes in modifiers that
would not be penetrant on an otherwise wild-type background.
This sensitivity often permits a dominant screen, decreasing the
time and resources required to identify new mutations.
Complete deficiency of many signaling molecules results in
loss of the cell type of interest or pleiotropic or lethal pheno-
types, making the effects of additional mutations difficult to
interpret. This can be addressed by starting a modifier screen
with a weak allele that either (i) reduces the signal strength to
just above the threshold for a productive response or (ii) presents
with a phenotype intermediate between wild-type and complete
deficiency (4, 5). Both enhancers and suppressors can thus be
characterized, and the pathway of interest studied in isolation.
This approach has been used in large scale, random screens (4,
5) and to probe interactions between previously defined muta-
tions. Many of the latter studies have been performed in mice.
These have identified interactions between such genes as SOS
and the epidermal growth factor receptor (6), Apc, and
Dpc4(Smad4) (7), the basic helix–loop–helix transcription fac-
tors E2A, HEB, and EBF (8, 9), and components of the
LynySHP-1yCD22 B cell inhibitory pathway (10).
The importance of studying modifier effects in mammals is
illustrated by the effect of genetic background on the severity of
many human diseases. Mouse models have been developed for
several such diseases, including but not limited to systemic lupus
erythematosus (NZB x NZW), polycystic kidney disease (pcy),
and familial adenomatous polyposis (Min). Intraspecific back-
crosses have identified naturally occurring modifiers of each of
these disease phenotypes (11–13).
The severity of X-linked agammaglobulinemia (XLA) and its
murine counterpart X-linked immunodeficiency (xid) also de-
pends on genetic background (14, 15). XLA and xid result from
loss of function of Bruton’s tyrosine kinase (Btk) (reviewed in
refs. 16–18) and are characterized by blocks in B cell develop-
ment at the pre-B stage in XLA and at the immature to mature
transition in xid. The remaining B cells have impaired responses
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to several cell surface receptors including the B cell antigen
receptor (BCR), CD38, RP-105, and the IL-5 receptor. Type II
T-independent antigen responses are impaired, and B-1 cell
numbers are reduced.
Many studies have begun to define mechanisms by which Btk
mediates B cell development and function (reviewed in refs.
17–19). Conflicting results regarding the nature of the interac-
tion between Btk and several other signaling molecules have
been reported. Protein kinase Cb (PKCb) binds to and phos-
phorylates Btk in vitro, reducing Btk kinase activity (20). How-
ever, PKCb-deficient mice have an xid-like phenotype, suggest-
ing a positive interaction between these two proteins (21).
Similarly, although the Src family kinase Lyn activates Btk in vitro
(22, 23), Lyn has a net negative effect on Btk (24).
Several known genes have been identified as modifiers of xid
or Btk deficiency, including Lyn, CD40, MHC class II, and
OCA-B (refs. 24 and 25; reviewed in ref. 19). These studies can
only address whether these genes have a role independent of or
redundant with Btk because no functional Btk is expressed in the
mice carrying the second mutation. To look more directly and
quantitatively at the effect of mutations in various signaling
molecules on Btk-dependent pathways, we used a transgenic
mouse model in which a low dose of Btk (Btklo) behaves as a
partial loss of function mutant (26). Twenty-five percent of
endogenous Btk levels is sufficient to restore the IgMloIgDhi
mature B cells that are absent in Btk2/2 or xid mice. However,
BCR-induced proliferation and response to type II T cell
independent (TI-II) antigens (26, 27) are only partially rescued
to levels between those of xidyBtk2/2 and wild-type mice. A
2-fold increase in Btk expression in homozygous transgenic mice
leads to a significant increase in responses, indicating that Btk is
a limiting component of BCR signaling pathways. We asked
whether reduction in dosage or complete deficiency of a panel
of gene products (Table 1 and Fig. 1) implicated as Btk regu-
lators by either the xid-like phenotypes of their deficiencies or
whether in vitro physical andyor functional interactions would
modify the Btklo response to BCR cross-linking in vitro and the
TI-II antigen 2,4,6-trinitrophenyl (TNP)-Ficoll in vivo. Enhanc-
ers, suppressors, and genes with no effect were identified and
could be quantitatively ranked.
Materials and Methods
Mice. Btklo mice carry a murine Btk cDNA transgene driven by
the Ig heavy chain promoter and enhancer on a Btk2/2 or Btk2/Y
background (26). The transgene expresses about 25% of endog-
enous Btk protein levels in splenic B cells. Btklo females were
mated with mice deficient in each candidate gene (C) to generate
pups that were C1/2 and either Btk2/Y, Btk2/Y tg (Btklo), Btk1/2,
or Btk1/2 tg. Mice were genotyped by PCR or Southern blot
analysis as described (21, 26, 29, 34, 36, 40–42, 48) except for
CD19 (37) and CD22 (38) mutant mice that were identified by
FACS analysis of peripheral blood. Males and females from
these crosses were then mated to each other. Informative
progeny were Btklo (Btk2/Y tg or Btk2/2 tg) and C1/1, C1/2, or
C2/2. Wild-type and Btk-deficient mice were used as controls.
Mice were on a mixed (C57BLy6 3 129 x BALByc) background.
Because the phenotype of Btk deficiency varies with genetic
background (14, 15), littermates were compared within each
experiment, and all results were confirmed with mice generated
from independent crosses. Mice were 6–12 weeks old when used
in experiments.
Flow Cytometry: Phenotypic Analysis. Single-cell suspensions of
spleens or peripheral blood were depleted of red blood cells by
a 5-min incubation in 0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM
Na2EDTA and stained with combinations of the following Abs:
anti-B220 Tri-Color (Caltag, South San Francisco, CA), anti-
IgD FITC (PharMingen), anti-IgM biotin (PharMingen),
streptavidin-phycoerythrin (PE) (Dako), anti-CD19 FITC
(PharMingen), anti-CD22 FITC (PharMingen), and anti-
B220-PE (PharMingen). Data were acquired on a FACScan
(Becton Dickinson) and analyzed by using CELLQUEST software.
Live cells were gated based on forward and side scatter.
B Cell Proliferation Assays. Total splenocytes were depleted of red
blood cells and plated in RPMI 1640 with 10% heat-inactivated
FCS at 106yml. Where indicated, goat anti-mouse IgM F(ab9)2
fragments (Jackson ImmunoResearch Laboratories) were added
at either 2 or 20 mgyml. At 24 h, BrdUrd (Sigma) was added to
a final concentration of 10 mM. Cells were harvested at 48 h,
stained with anti-BrdUrd FITC (Becton Dickinson) and anti-
B220 PE (PharMingen) as described (24), and analyzed on a
FACScan (Becton Dickinson) by using CELLQUEST software.
ELISA. Mice were immunized i.p. with 10 mg TNP-Ficoll (Bio-
search Technologies) and bled 6 days later. The 96-well plates
were coated with 25 mgyml TNP-BSA (Biosearch Technologies)
in PBS. Serum was diluted serially into PBS, 0.1% BSA, and
0.05% Tween-20 and added to wells in duplicate. Plates were
washed, incubated with secondary Ab (goat anti-mouse IgM-
alkaline phosphatase; Southern Biotechnology Associates) di-
luted 1:500 in PBS, 0.1% BSA, and 0.05% Tween-20, and
developed with an alkaline phosphatase substrate kit (Bio-Rad).
Table 1. B cell phenotype of candidate gene knockouts
Gene Viability Knockout phenotype Ref.
Lyn Viable 2 B cell numbers,2 surface IgM
levels,1 BCR responses,1
serum IgM levels, slightly2
T-dependent and
T-independent responses,1
B-1 cells, autoantibodies with
age
24, 28–32
Fyn Viable Normal B cell numbers, normal




Like xid with more severe block
at proB to preB stage
35, 36
CD19 Viable 2 B cell numbers,2 BCR





Gaq Viable No B cell phenotype described 40
Ga11 Viable No B cell phenotype described 41
SHIP Viable 2 B cell numbers,2 surface IgM
levels,1 BCR responses,2
FcgRIIb-mediated inhibition of






In 1/2 mice:1 number of
activated B cells (polyclonal
expansion),1 autoantibodies
45–49








PKCb Viable Like xid 21
The B cell phenotypes of mice deficient in each candidate gene tested are
indicated.
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OD405 was read on a Vmax kinetic microplate reader (Molecular
Devices).
Results
General Experimental Strategy. We asked whether a reduction in
dosage or complete deficiency of a panel of genes shown to
regulate Btk (Fig. 1, Table 1) would modify the Btklo phenotype.
In a two-step cross, mice carrying a targeted mutation in each
candidate gene (21, 29, 34, 36–38, 40–42, 48) were mated with
Btklo mice (24, 26) to generate progeny that were Btklo and either
C1/1, C1/2, or C2/2. Wild-type and Btk-deficient mice were used
as positive and negative controls, respectively, for Btk-dependent
responses. In the case of p85a (36) or phosphatase and tensin
homolog (PTEN), where complete deficiency is lethal (45–48),
and PKCb where loss of function mimics xid (21), only C1/2 mice
were tested. Because the phenotype of Btk deficiency varies with
genetic background (14, 15), littermates were compared within
each experiment and all results were confirmed with mice
generated from independent crosses. We chose two independent
assays of Btk-dependent processes, BCR-induced B cell prolif-
eration in vitro and TNP-Ficoll response in vivo. The first
measures a relatively well-defined process (53), whereas the
second involves complex, kinetic interactions between multiple
cell types and their microenviroment that are likely regulated by
a network of signaling pathways (54). To control for effects of
modifiers that did not involve regulation of Btk signaling path-
ways, we measured B cell numbers and Btk expression in resting
splenic B cells purified by anti-B220 Ab bound to magnetic
beads. In the case of CD192/2 Btklo mice, a slight reduction in
Btk protein levels was observed (data not shown). No other
changes in transgene-directed protein expression were seen in
resting cells.
Selection of Candidate Genes. Two major pathways are required for
the activation of Btk on BCR cross-linking (Fig. 1). First,
phosphatidylinositol 3,4,5-triphosphate (PIP3), the product of
phosphoinositide 3-kinase (PI3K), binds to the pleckstrin ho-
mology domain of Btk (55, 56) and targets Btk to the membrane
(Fig. 1 A) (57–60). This pathway is stimulated by CD19 (61, 62),
a cell surface molecule that functions to reduce B cell signaling
thresholds and amplify BCR signals. PI3K-mediated Btk mem-
brane association is inhibited by FcgRIIb via two mechanisms.
The first is mediated by SH2-containing inositol phosphatase
(SHIP) (57, 58), which dephosphorylates PIP3. The second
prevents the CD19yPI3K association (63). CD22, a cell surface
protein that generally inhibits BCR signaling, opposes CD19
(64–66) and therefore may inhibit the PI3KyBtk pathway as well.
Once at the membrane, Btk is transphosphorylated at Y551 by
Src family kinases (Fig. 1B) (22, 23). Btk then autophosphory-
lates at Y223 in the SH3 domain (23, 67) and becomes fully
active. CD19 feeds into this pathway by amplifying BCR-induced
activation of Src family kinases (68). CD22 may interfere
with this stage of Btk activation through its opposition of
CD19 (64–66).
Other proteins also regulate Btk via different pathways (Fig.
1B). Btk and PKCb have a complex interaction. PKCb inhibits
Btk activity in vitro (20), but the phenotype of PKCb2/2 mice
resembles xid (21). Btk may also transmit G protein-coupled
receptor initiated signals. Members of the q and 12 families of
heterotrimeric G protein a subunits have been claimed to
directly activate Btk in vitro (69, 70). There is no direct genetic
evidence to support this observation.
Based on this model, we predicted that reduced dosage or loss
of function of the positive regulators Lyn and Fyn (Src family
kinases), p85a, CD19, Gaq, and its close relative Ga11 would
enhance the Btklo phenotype, shifting it toward xid or Btk
deficiency. In contrast, mutation of CD22 and molecules that
down-regulate PIP3 levels such as the inositol phosphatases
SHIP and PTEN (ref. 48; reviewed in ref. 71) would likely
suppress the Btklo phenotype and shift it toward wild type. The
net effect of PKCb haploinsufficiency could not be predicted.
SHIP, PTEN, and Lyn Are Btklo Suppressors in the in Vitro Proliferation
Assay. We first tested whether we could identify modifiers that
regulated the mitogenic response of Btklo B cells to BCR
cross-linking in vitro. As predicted, all regulators of PIP3 levels
tested affected the performance of Btklo cells in this assay to
some degree. SHIP and PTEN were Btklo suppressors, as B cells
from PTEN1/2Btklo and SHIP2/2Btklo mice proliferated signif-
icantly better than Btklo cells (Fig. 2A), even in the absence of
FcgRIIb engagement. In both cases, the effect was mild (2-fold)
and observed only at low doses of anti-IgM (Fig. 2 A and B). A
small enhancing effect of p85a haploinsufficiency was observed
in some, but not all, animals at low doses of cross-linking Ab (Fig.
2A). However, this was not statistically significant.
Surprisingly, Src family kinases did not behave as expected.
Lyn, which was predicted to be an enhancer based on its
activation of Btk in biochemical studies (22, 23), was instead an
extremely strong suppressor. Both Lyn1/2Btklo and Lyn2/2Btklo
Fig. 1. Interactions of candidate modifiers with Btk. The major pathways for
Btk activation, mediated by PI3K (A) and Src family kinases (B), are indicated.
Double arrows represent interactions critical for Btk activation. Pathways that
inhibit, or are predicted to inhibit, Btk are indicated by ¢.









B cells responded better (up to 10-fold) to BCR cross-linking
than Btklo cells (ref. 24; Fig. 2 A and B). At low doses of anti-IgM,
Lyn2/2Btklo cells proliferated even better than wild-type cells.
This activity was specific to Lyn, as Fyn loss of function did not
change the response of either Btklo or Btkwt cells to BCR
cross-linking.
In addition to Fyn, CD19, CD22, PKCb, Gaq, and Ga11 failed
to modify this aspect of the Btklo phenotype (Fig. 2 A and B, and
data not shown).
CD19 and p85a Are Btklo Enhancers in the in Vivo Immune Response
Assay. It was unexpected that only 3 of 10 candidate genes had
significant effects on the transmission of BCR signals by Btk in
vitro. We also tested each candidate gene in an alternative
measurement of Btk-mediated B cell function, the production of
Abs in vivo in response to the TI-II antigen TNP-Ficoll. This
response depends on both an antigen-induced proliferative burst
and a spectrum of additional complex events (54). It was
modified quite differently than BCR-stimulated mitogenesis in
vitro. None of the suppressors identified in vitro affected the
TNP-Ficoll response of Btklo cells (Fig. 2), despite the fact that
SHIP2/2 mice display an enhanced IgG response to this antigen
(44). Fyn, CD22, PKCb, Gaq, and Ga11 also had no effect (data
not shown). In contrast, CD19 deficiency and p85a haploinsuf-
ficiency enhanced the Btklo phenotype in the TI-II antigen
response assay (Fig. 2C). The effect of CD19 was particularly
striking. CD192/2Btklo mice resembled Btk2/2 mice in their
complete failure to mount a TNP-Ficoll response (Fig. 2C). In
neither case could the reduced response be attributed to altered
B cell numbers. Btklo mice and p85a1/2Btklo mice had similar
numbers of mature splenic B cells (7.0 vs. 6.7 3 106).
CD192/2Btklo mice did have a 2-fold reduction in the size of the
mature B cell population relative to Btklo mice. However, mature
B cell numbers were increased 2-fold compared with CD192/2
mice, which have relatively normal or even enhanced responses
to TNP-Ficoll (refs. 39 and 72; data not shown).
Discussion
Insights into Btk Signaling. Although this study does not address
the mechanism of modification by the genes identified here, it
begins to define the relative contribution of these molecules to
Btk-dependent processes. In some cases, the nature of these
genetic interactions could not have been predicted by data from
in vitro, biochemical, or cell culture studies.
Strikingly, all suppressors affected the response to BCR
cross-linking in vitro but not TNP-Ficoll immunization in vivo. In
contrast, enhancers altered only the in vivo response. This
finding suggests that TI-II responses require a stronger Btk signal
than anti-IgM-induced proliferation. Consistent with this idea,
the amount of Btk protein required for an efficient TNP-Ficoll
response is higher than that needed for a mitogenic response to
BCR cross-linking (26). Alternatively, Btk may participate in
non-BCR-mediated, or nonproliferation-dependent, processes
that regulate TI-II responses. These might include the develop-
ment of an appropriate B cell repertoire, migration of antigen-
specific B cells to the correct microenvironment, cytokine-
dependent B cell proliferation and differentiation, or antigen
presentation (54).
The strong suppression of some aspects of the Btklo phenotype
by Lyn (ref. 24, Fig. 2 A) was unexpected. Several Src family
kinases may be redundant for the activation of Btk (22, 23, 33,
34), whereas Lyn has a unique inhibitory role (24, 29). Down-
regulation of BCR signals by Lyn can occur via CD22ySHP-1-
mediated (10, 28, 73, 74) and FcgRIIbySHIP-mediated (28, 30,
74) pathways. CD22 was not a Btklo modifier, suggesting that the
LynyCD22ySHP-1 inhibitory pathway is redundant or does not
impinge on Btk. In contrast, some SHIP-dependent inhibition of
Btk signaling was seen. This did not account for all of the
Fig. 2. (A and B) Lyn, SHIP, and PTEN modify the Btklo response to BCR
cross-linking in vitro. Splenocytes from 6- to 12-week-old Btklo mice either
1y1 ( n ), 1y2 (u), or 2y2 (h) for each candidate gene were incubated for 48 h
with 2 (A) or 20 (B) mgyml of goat anti-mouse IgM F(ab9)2 fragments. Cells were
labeled with BrdUrd for the final 24 h. The percentage of B2201 cells labeled
with BrdUrd was determined by flow cytometry. (C) CD19 and p85a modify the
Btklo response to TNP-Ficoll in vivo. Six- to 12-week-old Btklo mice either 1y1
( n ), 1y2 (u), or 2y2 (h) for each candidate gene were immunized with 10 mg
TNP-Ficoll and bled 6 days later. Serum was diluted serially, and anti-TNP IgM
was measured by ELISA. The results shown are from a 1:400 dilution of serum,
which was within the linear range.(A–C) To compare results from several
experiments, data were normalized to the average response of Btklo cells,
which was arbitrarily set to 1. Data are presented as mean 6 SEM (n .5 4).
Results significantly different from Btklo by Student’s t test (P , 0.05) are
indicated by asterisks above the appropriate bars. p85a, PTEN, and PKCb2/2
mice were not tested because of lethality or xid-like phenotype.
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inhibition observed with Lyn, suggesting that additional mech-
anisms contribute to Lyn-mediated down-regulation of Btk
pathways. These may include inhibition by the cell surface
receptor PIR-B, a pathway shown to involve both Btk and Lyn
(75, 76).
The mild suppression of the Btklo phenotype by both SHIP
deficiency and PTEN haploinsufficiency suggests that SHIP and
PTEN might be partially redundant in down-regulating BCR
signaling pathways. PTEN is likely more dominant, at least in the
absence of FcgRIIb engagement, based on the observed gene
dosage effect. SHIP and PTEN may also have indirect effects on
the proliferation of Btklo B cells. It has recently been shown that
the absence of SHIP results in increased Akt phosphorylation
and enhances the survival of B cells following stimulation with
the F(ab9)2 fragment of anti-IgM (44). PTEN is known to inhibit
the anti-apoptotic PI3KyPIP3yAkt pathway (48) (reviewed in
ref. 71). Impaired down-regulation of Akt may increase survival
of PTEN1/2Btklo or SHIP2/2Btklo B cells, indirectly enhancing
proliferation.
The reduced TNP-Ficoll responses in both CD192/2Btklo and
p85a1/2Btklo mice supports a model in which CD19 amplifies
Btk activation via PI3K (61, 62). p85a was more penetrant than
CD19, however. An effect of haploinsufficiency of p85a, but not
CD19, was observed in the context of a limiting dose of Btk. In
addition, the consequences of p85a deficiency for B cell prolif-
eration and response to TI-II antigens (35, 36) are much more
severe than those of CD19 deficiency (37–39) in the presence of
normal levels of Btk. PI3K is likely activated by both CD19-
dependent and CD19-independent mechanisms in response to
BCR cross-linking.
PKCb, Fyn, CD22, Gaq, and Ga11 failed to modify the Btklo
phenotype in either assay. A similar lack of genetic interaction
between known components of a biochemical pathway was
observed in a screen for modifiers of the rough-eye phenotype
produced by an activated form of Ras expressed in the Drosoph-
ila eye (5). Although both Raf and mitogen-activated protein
(MAP) kinase are known to be downstream of Ras, only 1 allele
of Raf was identified out of 850,000 mutagenized progeny in
comparison to more than 100 alleles of MAP kinase. This type
of result could indicate that genes that do not modify as expected
are redundant, not limiting, or have balanced activating and
inhibitory effects on the pathway of interest. The latter scenario
is particularly likely in the case of PKCb, given that both positive
(21) and negative (20) interactions between PKCb and Btk have
been shown in other systems. It is also possible that these genes
do interact with Btk, but in pathways used by receptor systems
not tested here.
A Mammalian, Sensitized Genetic System for the Identification of New
Mutations. Btklo mice are an excellent sensitized genetic system
with which to identify functional interactions between compo-
nents of B cell signaling pathways. Because the mechanism by
which Btk signaling is modified varies among functional re-
sponses, an extension of these studies to other Btk-dependent
pathways such as CD38, RP105, and IL-5 (reviewed in refs.
17–19) would likely demonstrate additional types of interactions.
Most importantly, haploinsufficiency of Lyn, PTEN, or p85a
modified the Btklo phenotype. A dominant screen can therefore be
undertaken for additional strong modifiers. Screening for pheno-
types of heterozygous mutations would, like the cre-lox (77) or
Rag2-complementation (78) systems, circumvent the lethal or
pleiotropic effects of some complete deficiencies. This would allow
the identification of a role for these genes within B cells. These
observations set the stage for a genome-wide, random mutagenesis
approach to identify novel modifiers by using the serological
immune response to TI-II antigens as an assay.
This approach is not limited to the study of Btk-mediated
processes. Reduction in dosage or functional activity of any
combination of gene products by heterozygous mutation, trans-
gene replacement, or ‘‘knocking-in’’ point mutations or small
deletions by using homologous recombination in embryonic
stem cells could reveal genetic interactions. These types of
studies will be valuable for defining physiologically relevant
signaling pathways and quantifying the processes affected in
polygenic disorders.
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